💉 Add tirzepatide to biologics in obese #PsA? #POS0050: Yes! Propensity score-matched study (n=93): better PROs, HAQ & PASI at 6 months #EULAR2026 @RheumNow @vincevenerito https://t.co/rrhNKZByjc

• https://x.com/Nellziade/status/2062192025965883481/photo/1

🎯 Does Tofacitinib work in axial #PsA? #POS0049: 1st RCT (PASTOR, n=26): improved MRI & clinical outcomes vs placebo @ wk12 #EULAR2026 @rheumnow

Nail #PsA, hard to treat and often overlooked. APEX trial: guselkumab achieved 43% ↓ in nail severity score (mNAPSI) vs 16% worsening on placebo at wk 24, plus PASI 100 in ~39% vs 11%. IL-23 inhibition delivering where pts often struggle most. @RheumNow #EULAR2026 POS0471

BKZ protect joints in #PsA long-term? #POS0048: Phase 3 RCT+OLE (n=579): 74% no x-ray progression at 3 yrs, across all subgroups 💪 #EULAR2026 @RheumNow https://t.co/BftcHDKS4l

• https://x.com/Nellziade/status/2062190936398958715/photo/1

💉 Risankizumab durable in #PsA? #POS0047 3 RCT n=964 KEEPsAKE Yes! ACR50 ~37% & MDA ~34% @w244 no new safety signals 💪 #EULAR2026 @RheumNow https://t.co/911Fi9vxfP

• https://x.com/Nellziade/status/2062190496227692664/photo/1

🤔 Best endpoint for #PsA trials? #POS0046: GRAPPA-OMERACT NMA (24 trials, n=12,000): MDA wins! (OR 5.06) 📊 #EULAR2026 @RheumNow https://t.co/3KWaKcvF0a

• https://x.com/Nellziade/status/2062189374968578357/photo/1

🤔 GUS or IL-17i for #PsA? #POS0045: RW study: Both! ~76% persistence & similar effectiveness 1141 pts @12mo #PsABIOnd 🌍 #EULAR2026 @RheumNow https://t.co/PyuaH5B5V1

• https://x.com/Nellziade/status/2062188852073177480/photo/1

In #PsA, obesity isn't just a comorbidity, it's a disease modifier. Pooled SPIRIT trials (n=1284): 43% had obesity. BMI≥30 vs normal: joint counts ↑, function ↓, fatigue ↑, CVD 55% vs 18%, HTN 52% vs 11%, DM 19% vs 3%. @RheumNow #EULAR2026 POS0460

Guselkumab in erosive #PsA: ACR20 68% vs 47% placebo, structural damage progression ↓ across subgroups regardless of sex, BMI, MTX use, or joint counts. Highest inflammation and erosion burden? Biggest benefit. IL-23i holds up where it matters most. @RheumNow #EULAR2026 POS0480

Not all "difficult-to-treat" #PsA definitions are equal. Real-world DEPAR cohort (n=885): 20% met GRAPPA complex-to-manage vs only 4% EULAR difficult-to-manage criteria. Definition choice determines who gets identified, and who gets left behind. @RheumNow #EULAR2026 POS0446

IL-23i vs IL-17i in PsABIOnd (n=1,141): 12mo persistence (~77%), joint/skin response, MDA, and PROs similar across both. GUS matched IL-17i despite treating more biologic-experienced pts (15% vs 8% on 4th-line). GI AEs higher with IL-17i (11% vs 7%). @RheumNow #EULAR2026 POS0045

What’s new in (WIN) PsA session. A preview of the BE BOLD study: Bimekizumab vs risankizumab on ACR50 in active #PsA 49.1% vs 38.4% (p=0.008). The first head-to-head biologic trial to show joint superiority in PsA. Dual IL-17A/F blockade important. Abstr #LB0001 @RheumNow

What’s in the pipeline for #psoriatic_arthritis treatment? A special focus on Tyk2 inhibitors WIN session at #EULAR2026 @RheumNow https://t.co/dDJtmdx9xU

• https://x.com/Nellziade/status/2062174411789050339/photo/1

What is new in PsA? Dennis McGonagle's take at #EULAR2026 -a strong year for discovery in mechanisms of transition from PSO to PsA -publication of the first single cell atlas Enthesis -Better understanding of VTE mechanisms in JAKi in PsA -clinical aspects of Axial involvement https://t.co/v9cfn1y4fH

• https://x.com/AurelieRheumo/status/2062175008340730028/photo/1